Becton Dickinson and Company (BDX) has completed a strategic spin-off of its Biosciences and Diagnostic Solutions business, creating Augusta SpinCo Corporation in collaboration with Waters Corporation and valued at $4 billion. The company reported revenues of $5,252 million and net income of $382 million for Q4 2025, despite ongoing pricing and demand challenges. Following this divestiture, BDX plans to use the proceeds for debt reduction and share repurchases while reorganizing into five global business segments to enhance operational focus.
“Becton Dickinson & Co. · rose · percentage · 0.70%”
“Becton, Dickinson and Company · is a · medical technology firm · leading global”
“Becton, Dickinson and Company · spun off · Biosciences & Diagnostic Solutions business · with Waters Corporation”
“Becton, Dickinson and Company (BDX) · has announced a spinoff of · Biosciences and Diagnostics Solutions business · Augusta SpinCo Corporation”
“BD · provides · forward-looking statements · estimates regarding future prospects and performance”
“BD · reported · revenues for Q4 2025 · $5,252 million”
“BD · reported · net income for Q4 2025 · $382 million”
“BD · has cash and equivalents · as of December 31, 2025 · $740 million”
“BD · reported · total assets · $54,841 million”
“Becton Dickinson and Company · reported · net income · $382 million”
“Becton Dickinson and Company · recorded · revenues · $5,252 million”
“Becton Dickinson and Company · incurred · research and development expense · $306 million”